Form 4: Cumberland Pharmaceuticals Director James Jones Acquires 1,000 Shares

Director James Jones of Cumberland Pharmaceuticals Inc. reports acquiring 1,000 shares of common stock at $1.71 per share on March 25, 2024.

Summary

• On March 25, 2024, James Jones, a director of Cumberland Pharmaceuticals Inc., acquired 1,000 shares of common stock.
• The shares were acquired at a price of $1.71 per share.
• Following the transaction, Jones directly owns 33,407 shares of Cumberland Pharmaceuticals Inc.
• The acquisition was made via a restricted stock award that will vest 100% on March 25, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock transaction by a company director. The purchase itself could be seen as mildly positive, but the document is primarily informational.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's recent stock purchase, which is a common occurrence.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates